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A B S T R A C T
Background
Cholelithiasis refers to the presence of gallstones, which are concretions that form in the biliary tract, usually in the gallbladder.
Cholelithiasis is one of the most common surgical problems worldwide and is particularly prevalent in most Western countries.
Biliary colic is the term used for gallbladder pain experienced by a person with gallstones and without overt infection around the
gallbladder. It is the most common manifestation of cholelithiasis, observed in over one-third of people with gallstones over the course
of 10 or more years. Non-steroid anti-inflammatory drugs (NSAIDs) have been widely used to relieve biliary colic pain, but their
role needs further elucidation. They may decrease the frequency of short-term complications, such as mild form of acute cholecystitis,
jaundice, cholangitis, and acute pancreatitis, but they may also increase the occurrence of more severe and possibly life-threatening
adverse events such as gastrointestinal bleeding, renal function impairment, cardiovascular events, or milder events such as abdominal
pain, drowsiness, headache, dizziness, or cutaneous manifestations.
Objectives
To assess the benefits and harms of NSAIDs in people with biliary colic.
Search methods
We searched theCochraneHepato-BiliaryControlledTrialsRegister, CochraneCentral Register ofControlledTrials (CENTRAL) in the
Cochrane Library,MEDLINE (Ovid SP), Embase (Ovid SP), ScienceCitation Index Expanded (Web of Science), andClinicalTrials.gov
until July 2016. We applied no language limitation.
Selection criteria
Randomised clinical trials recruiting participants presenting with biliary colic and comparing NSAIDs versus no intervention, placebo,
or other drugs.
Data collection and analysis
Two review authors (MF and AC) independently identified trials for inclusion. We used risk ratios (RR) to express intervention effect
estimates, and we analysed the data with both fixed-effect and random-effects model meta-analyses, depending on the amount of
heterogeneity. We controlled random errors with Trial Sequential Analysis. We assessed the methodological quality of the evidence
using GRADE criteria.
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Main results
Twelve randomised clinical trials (RCTs) met our predefined review protocol criteria for analysis. We found only one trial to be at low
risk of bias, considering the remaining trials to be at high risk of bias. The risk of selection bias in nine studies was unclear due to
poor reporting, leading to uncertainty in the pooled effect estimates. Five trials compared NSAIDs versus placebo, four trials compared
NSAID versus opioids, and four trials compared NSAID versus spasmolytic drugs (one of the 12 trials was a three-arm study comparing
NSAIDs versus both opioids and spasmolytic drugs). There were 828 randomised participants (minimum 30 and maximum 324 per
trial), of whom 416 received NSAIDs and 412 received placebo, spasmolytic drugs, or opioids. Twenty-four per cent of the participants
were males. The age of the participants in the trials ranged from 18 to 86 years. All people were admitted to emergency departments
for acute biliary pain. There was no mortality. When compared with placebo, NSAIDs obtained a significantly lower proportion of
participants without complete pain relief (RR 0.27, 95% confidence interval (CI) 0.19 to 0.40; I2 = 0%; 5 trials; moderate-quality
evidence), which was confirmed by Trial Sequential Analysis, but not regarding participants with complications (RR 0.66, 95% CI
0.38 to 1.15; I2 = 26%; 3 trials; very low-quality evidence). NSAIDs showed more pain control than spasmolytic drugs (RR 0.51, 95%
CI 0.37 to 0.71; I2 = 0%; 4 trials; low-quality evidence), which was not confirmed by Trial Sequential Analysis, and a significantly
lower proportion of participants with complications (RR 0.27, 95% CI 0.12 to 0.57; I2 = 0%; 2 trials; low-quality evidence), which
was also not confirmed by Trial Sequential Analysis. We found no difference in the proportions of participants without complete pain
relief when comparing NSAIDs versus opioids (RR 0.98, 95% CI 0.47 to 2.07; I2 = 52%), suggesting moderate heterogeneity among
trials (4 trials; very low-quality evidence). Only one trial comparing NSAIDs versus opioids reported results on complications, finding
no significant difference between treatments. None of the included trials reported severe adverse events. Seven out of the 12 trials
assessed non-severe adverse events: in two out of the seven trials, adverse events were not observed, and minor events were reported in
the remaining five trials.
In addition, we found one ongoing RCT assessing the analgesic efficacy of intravenous ibuprofen in biliary colic.
Authors’ conclusions
NSAIDs have been assessed in relatively few trials including a limited number of participants for biliary colic, considering its common
occurrence. We found only one trial to be at low risk of bias. There was no mortality. None of the included trials reported quality of
life. The generalisability of the review is low as most of the RCTs included neither elderly people nor participants with comorbidities,
who are more prone to complications as compared to others with biliary colic.
The beneficial effect of NSAIDs compared with placebo on pain relief was confirmed when we applied Trial Sequential Analysis.
The quality of evidence according to GRADE criteria was moderate for the comparison of NSAIDs versus placebo regarding the
outcome lack of pain relief and low or very low for the other outcomes and comparisons.
We found only one trial at low risk of bias, following the predefined ’Risk of bias’ domains. We found the risk of selection bias to be
unclear in nine studies due to poor reporting, leading to uncertainty in the pooled effect estimates.
P L A I N L A N G U A G E S U M M A R Y
Non-steroid anti-inflammatory drugs for biliary colic
Background
Non-steroid anti-inflammatory drugs (NSAIDs) such as diclofenac, ketorolac, tenoxicam, flurbiprofen, etc. are commonly used to
relieve biliary colic pain.
Study characteristics
We searched for randomised clinical trials recruiting participants presenting with biliary colic and comparing NSAIDs versus no
intervention, placebo, or other drugs.
Key results
We included 12 randomised clinical trials with 828 participants, of whom 416 received NSAIDs and 412 received placebo, spasmolytic
drugs, or opioids, in the review. Considering the common occurrence of biliary colic, these numbers of trials and participants are
insufficient. Elderly participants and participants with co-morbidities were poorly represented in the trials. Twenty-four per cent of the
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participants were males. The age of participants ranged from 18 to 86 years. All people were admitted to emergency department for
acute biliary pain. There was no mortality. None of the included trials reported quality of life. We found that NSAIDs significantly
reduced biliary pain when compared with placebo and spasmolytic drugs. NSAIDs also significantly reduced cholelithiasis-related
complications (e.g. acute cholecystitis, acute pancreatitis, jaundice, cholangitis) as compared to placebo and spasmolytic drugs. One
trial comparing NSAIDs versus opioids reported results on complications, finding no significant difference between treatments.
None of the trials reported major adverse events. Seven out of 12 trials reported minor adverse events; in two out of the eight trials
adverse events were not observed, and minor events were reported in the remaining five trials.
We found one ongoing randomised clinical trial aimed at assessing the analgesic effectiveness of intravenous ibuprofen in biliary colic.
Funding
The trials appeared to be free of industry sponsorship or other type of for-profit support that may manipulate the trial design,
conductance, results, or conclusions of the trial.
Quality of evidence
The quality of evidence according to GRADE criteria (a system developed to grade evidence and recommendations in health care) was
moderate for the comparison NSAIDs versus placebo for the outcome lack of pain relief and low or very low for the other outcomes
and comparisons.
Only one of 12 trials was at low risk of bias following predefined ’Risk of bias’ domains.
The results of the present systematic review with meta-analysis suggest that NSAIDs can be used for pain relief, but further randomised
clinical trials are warranted, and NSAIDs should be used with care in certain patient groups, such as the elderly and people with co-
morbidities.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Non-steroid anti- inflammatory drugs versus placebo for biliary colic
Patient or population: people with biliary colic
Settings: emergency departments
Intervention: NSAIDs versus placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control NSAIDs versus placebo
Lack of pain relief Study population RR 0.27
(0.19 to 0.4)
208
(5 studies)
⊕⊕⊕©
moderate1
784 per 1000 212 per 1000
(149 to 314)
M oderate
800 per 1000 216 per 1000
(152 to 320)
Cholelithiasis- related
complications
Study population RR 0.66
(0.38 to 1.15)
140
(3 studies)
⊕©©©
very low2,3
471 per 1000 311 per 1000
(179 to 541)
M oderate
318 per 1000 210 per 1000
(121 to 366)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; NSAIDs: non-steroid ant i-inf lammatory drugs; RR: risk rat io4
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded one level (-1) for risk of bias because the overall risk of bias in four out of f ive studies was unclear.
2Downgraded one level (-1) for risk of bias because the overall risk of bias in two out of three studies was unclear.
3Downgraded two levels (-2) for imprecision: wide 95% CI overlapping 1 and including appreciable benef its (RR < 0.75); the
required information size was not reached.
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B A C K G R O U N D
Description of the condition
Cholelithiasis refers to the presence of gallstones, which are con-
cretions that form in the biliary tract, usually in the gallbladder.
Cholelithiasis represents one of the most common surgical prob-
lems worldwide and is especially prevalent in most Western coun-
tries. In the USA alone, gallstones are present in 8% to 20% of the
population by the age of 40 years, and are more likely to develop in
women than in men by a ratio of between 2 and 3 to 1 (Friedman
1993; Johnson 2001). Mexican-Americans and American Indians
also seem to have an increased risk for the development of gall-
stones, and in all cultures, the incidence increases as age increases.
A population of male civil servants in Rome, Italy, was investigated
to determine the prevalence of symptomatic and asymptomatic
gallstone disease. In this study, in which 71.5% of the popula-
tion participated, the prevalence of gallstone disease was 8.2%,
and increased from 2.3% in the 20- to 25-year-old age group to
14.4% in the 60- to 69-year-old age group, based on both pres-
ence of gallstones and history of cholecystectomy.About one-third
of the men with gallstone disease had previously been submitted
to cholecystectomy. Overall, 7.7% of the men with presence of
gallstones had complained of at least one episode of biliary pain
in the preceding five years (Grepco I 1988). In another, more re-
cent study performed in a random sample of women belonging to
a rural population, during a 10-year longitudinal follow-up, the
overall 10-year incidence of gallstone disease was 6.3% (5.5% of
new gallstones and 0.8% of cholecystectomies) (Angelico 1997).
More than three-quarters (76.9%) of these women had not suf-
fered biliary pain (Angelico 1997). Out of the initially asymp-
tomatic gallstone women, 15.4% experienced at least one episode
of biliary pain, 23.1% underwent elective cholecystectomy, and
61.5% remained asymptomatic (Grepco II 1988). The GREPCO
study reported a cumulative probability of developing biliary colic
in initially asymptomatic people of 11.9 ± 3.0% at two years and
25.8 ± 4.6% at 10 years (Attili 1995).
Description of the intervention
Non-steroid anti-inflammatory drugs (NSAIDs), opioid drugs,
and spasmolytic drugs have been widely used to relieve biliary
colic. NSAIDs are usually used as the first line of treatment.
How the intervention might work
NSAIDs’ pathophysiological mechanism of relieving pain is
thought to be related not only to their anti-inflammatory ac-
tion, but also to their smooth-muscle relaxant capacities (Thornell
1985;Goldman 1989; Brooks 1998;Morgan 1999).However, the
actual role of NSAIDs in biliary colic has yet to be clarified. It re-
mains unclear whetherNSAIDs decrease or increase the frequency
of short-term complications caused by gallstones. Simultaneously,
NSAIDs may increase the risk for more severe adverse events, in-
cluding those that are life-threatening. For instance, NSAIDs in-
terfere with platelet function, and thus may increase the risk of
bleeding after interventions such as surgery or endoscopic retro-
grade cholangiopancreatography (ERCP).
The usual first-line treatment for biliary colic isNSAIDs, but other
drugs can also be used. Opioid drugs include morphine, codeine,
and pethidine, which reduce the intensity of pain signals reaching
the brain and affect those brain areas that control emotion, in
this way diminishing the effects of a painful stimulus. Spasmolytic
drugs such as hyoscine butylbromide (also known as scopolamine)
inhibit the action of acetylcholine and stop the transmission of
parasympathetic nerve impulses, thus lessening the spasms of the
smooth muscle in the gastrointestinal tract and in the gallbladder.
Why it is important to do this review
Cholelithiasis is one of themost common surgical problemsworld-
wide and is especially prevalent in Western countries. Biliary colic
is the most common manifestation of cholelithiasis, developing in
at least one-third of people with gallbladder stones over a 10-year
follow-up period. NSAIDs have been widely used to relieve biliary
colic pain, but their role needs further elucidation. NSAIDs may
decrease the frequency of short-term complications caused by gall-
stones, such as amild form of acute cholecystitis, jaundice, cholan-
gitis, and acute pancreatitis, but they may simultaneously increase
the risk of more severe and possibly life-threatening events such
as gastrointestinal bleeding, renal function impairment, cardiovas-
cular events, or milder events such as abdominal pain, drowsiness,
headache, dizziness, or cutaneous manifestations.
There are only two non-Cochrane systematic reviews with meta-
analyses so far available. The first Spanish review compared
NSAIDs versus other drugs for biliary colic in people with
cholelithiasis (BasurtoOna 2008), and included seven randomised
clinical trials with 349 participants (Niinikoski 1984;Grossi 1986;
Camp 1992; Al Waili 1998; Dula 2001; Goldman 2001; Kumar
2004); all but one of these trials are included in our review
(Niinikoski 1984). We excluded Niinikoski 1984 from our re-
view because it compared two NSAIDs (indomethacin 50 mg and
metamizole 2.5 g). The second non-Cochrane review was pub-
lished by our own group (Colli 2012). In this review, we did not
grade the overall evidence and did not perform a Trial Sequential
Analysis to calculate the cumulative sample size of the meta-anal-
ysis (information size), thus running the risk of overestimating the
efficacy of NSAIDs in reducing biliary colic complications.
O B J E C T I V E S
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To assess the benefits and harms of NSAIDs in people with biliary
colic.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised clinical trials evaluating the possible benefits and
harms of NSAIDs in people with biliary colic. We included the
trials irrespective of blinding, year of publication, publication sta-
tus, or language.
For evaluation of harms, we included quasi-randomised clinical
studies and observational studies identified during our searches for
randomised clinical trials.
Types of participants
All people presentingwith biliary colic according to the definitions
and diagnostic work-up in the individual trials.
Types of interventions
We considered all types of NSAIDs as the experimental interven-
tion. We considered no intervention, placebo, or other drugs (e.g.
opioid, spasmolytic drugs) as control interventions, independently
of their route or schedule of administration.
We allowed collateral interventions if received equally by all par-
ticipants in the trial.
Types of outcome measures
Primary outcomes
1. Mortality.
2. Lack of pain relief. Number of people not experiencing pain
relief out of all the people treated as defined in the primary
studies.
Secondary outcomes
1. Number of people with cholelithiasis-related complications
(e.g. acute cholecystitis, acute pancreatitis, jaundice, cholangitis;
number of people manifesting bleeding from operative
intervention or ERCP less than 9, or both).
2. Quality of life.
3. Drug-related complications and adverse events, the latter
expressed as the number of people experiencing any event (e.g.
gastrointestinal bleeding, cutaneous rash, renal function
impairment, cardiovascular events, or any other events described
in the trials).
4. Quantification of pain relief rated in the trials on
quantitative scales.
5. The time needed to obtain pain relief: complete pain relief
or any small amount of pain relief (as defined by the different
trials).
Search methods for identification of studies
Electronic searches
We searched the Cochrane Hepato-Biliary Group Controlled Tri-
als Register (Gluud 2016; 31 July 2016), Cochrane Central Reg-
ister of Controlled Trials (CENTRAL; 2016, Issue 5) in the
Cochrane Library, MEDLINE (OvidSP; 1946 to 31 July 2016),
Embase (OvidSP; 1974 to 31 July 2016), Science Citation Index
Expanded (Web of Science; 1900 to 31 July 2016) (Royle 2003),
and ClinicalTrials.gov (www.clinicaltrials.gov) (31 July 2016). We
also searched ClinicalTrials.gov for ongoing studies. The search
strategies used and time spans of the searches can be found in
Appendix 1.
Searching other resources
We searched the proceedings of the major hepatological and sur-
gical congresses and references of included trials. In cases where
the full paper could not be retrieved or there were uncertainties,
we contacted the authors of the study.
Data collection and analysis
Selection of studies
Two review authors (MF, AC) read the abstract of each study iden-
tified by the search, eliminated studies that clearly did not satisfy
the inclusion criteria, and obtained full copies of the remaining
studies. The same review authors then independently read these
studies to determine eligibility; any disagreements were settled by
discussion, and reasons for exclusion were recorded. The two re-
view authors were unblinded with regard to the names of the au-
thors, investigators, institution, source, and results.
Data extraction and management
We designed standardised extraction sheets and piloted one before
use. Two review authors (AC, MF) independently extracted data
from the included trials. The extracted data included:
• participant characteristics: age, sex;
7Non-steroid anti-inflammatory drugs for biliary colic (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• experimental and control interventions (see above);
• outcomes (see above);
• trial quality characteristics (see below).
Assessment of risk of bias in included studies
Two review authors (MF, GC) independently assessed the risk
of bias of each included trial according to the recommendations
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), the Cochrane Hepato-Biliary Group Module (
Gluud 2016), and methodological studies (Schulz 1995; Moher
1998; Kjaergard 2001; Wood 2008; Lundh 2012; Savovi 2012;
Savovi 2012a).
We used the following definitions in the ’Risk of bias’ assessment.
Allocation sequence generation
• Low risk of bias: sequence generation was achieved using
computer random number generation or a random number
table. Drawing lots, tossing a coin, shuffling cards, and throwing
dice were adequate if performed by an independent person not
otherwise involved in the trial.
• Uncertain risk of bias: the method of sequence generation
was not specified.
• High risk of bias: the sequence generation method was not
random.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. Allocation
was controlled by a central and independent randomisation unit.
The allocation sequence was unknown to the investigators (e.g. if
the allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Uncertain risk of bias: the method used to conceal the
allocation was not described so that intervention allocations may
have been foreseen in advance of, or during, enrolment.
• High risk of bias: the allocation sequence was likely to be
known to the investigators who assigned the participants.
Blinding of participants and personnel
• Low risk of bias: it was mentioned that both participants
and personnel providing the interventions were blinded, and the
method of blinding was described, so that knowledge of
allocation was prevented during the trial.
• Unclear risk of bias: it was not mentioned if the trial was
blinded, or the trial was described as blinded, but the method or
extent of blinding was not described, so that knowledge of
allocation was possible during the trial.
• High risk of bias: the trial was not blinded, so that the
allocation was known during the trial.
Blinded outcome assessment
• Low risk of bias: it was mentioned that outcome assessors
were blinded, and the method of blinding was described, so that
knowledge of allocation was prevented during the trial.
• Unclear risk of bias: it was not mentioned if the trial was
blinded, or the trial was described as blinded, but the method or
extent of blinding the assessors was not described, so that
knowledge of allocation was possible during the trial.
• High risk of bias: the trial was not blinded, so that the
allocation was known to the assessors during the trial.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. Sufficient
methods, such as multiple imputation, were employed to handle
missing data.
• Uncertain risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk: the trial reported outcomes such as mortality; lack
of complete pain relief; and number of people with
cholelithiasis-related complications, drug-related complications,
and adverse events. If the original trial protocol was available, the
outcomes should be those called for in that protocol. If the trial
protocol was obtained from a trial registry (e.g.
ClinicalTrials.gov), the outcomes sought should have been those
enumerated in the original protocol if the trial protocol was
registered before or at the time that the trial was begun. If the
trial protocol was registered after the trial was begun, those
outcomes will not be considered to be reliable.
• Unclear risk: not all predefined outcomes were reported
fully, or it was unclear whether data on these outcomes were
recorded or not.
• High risk: one or more predefined outcomes were not
reported.
For-profit bias
• Low risk of bias: the trial appeared to be free of industry
sponsorship or other type of for-profit support that could
manipulate the trial design, conductance, or results of the trial.
• Uncertain risk of bias: the trial may or may not be free of
for-profit bias, as no information on clinical trial support or
sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received other type of for-profit support.
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Other sources of bias
• Low risk of bias: the trial appeared to be free of other
factors that could put it at risk of bias.
• Uncertain risk of bias: the trial may or may not have been
free of other factors that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias.
Review authors MF and AC judged trials to be at low risk of bias
if they were assessed as having low risk of bias in all of the above
domains. In all other cases, we judged the trials to be at high risk of
bias. We resolved any differences in opinion through discussion;
in the case of unsettled disagreements, review authors GC andDC
adjudicated.
We summarised results in both a ’Risk of bias’ graph and a ’Risk
of bias’ summary.
Measures of treatment effect
Wepresented dichotomous data as risk ratio (RR) with 95% confi-
dence interval (CI) and continuous outcomes as mean differences
(MD) with 95% CI.
Unit of analysis issues
The randomised participants in the trials.
Dealing with missing data
We contacted investigators of the trials to request missing data.We
performed all analyses according to the intention-to-treat analysis
method, that is analysing participants in the trials in the groups
to which they were randomised, regardless of whether they had
received or adhered to the allocated intervention.
Assessment of heterogeneity
We explored the presence of statistical heterogeneity by the Chi
2 test, with significance set at P value of less than 0.10. In case
of significant heterogeneity, we explored the possible sources of
heterogeneity by means of sensitivity analyses. In addition, we
used the I2 statistic to quantify the heterogeneity according to the
following classification: from 0% to 40%, heterogeneity may not
be important; from 30% to 60%, heterogeneity may be moderate;
from 50% to 90%, heterogeneity may be substantial; and from
75% to 100%, heterogeneity may be considerable.
Assessment of reporting biases
For any considered outcome where at least 10 trials were included
in themeta-analysis, we tested for funnel plot asymmetry (Higgins
2011).
Data synthesis
Meta-analysis
We performed meta-analyses following the recommendations re-
ported in the Cochrane Handbook for Systematic Reviews of Inter-
vention and theCochraneHepato-BiliaryGroupModule (Higgins
2011; Gluud 2016).
We applied both fixed-effect model, DeMets 1987, and random-
effects model, DerSimonian 1986, meta-analyses. If there were
statistically significant discrepancies in the results, we reported
both analyses.Otherwise, we reported the results obtainedwith the
fixed-effect model when heterogeneity was substantially absent (I
2 less than 10%) and reported the results obtained by the random-
effects model when heterogeneity was present.
We used the statistical package provided with Review Manager 5
for the meta-analysis (RevMan 2014).
Trial Sequential Analysis
We performed Trial Sequential Analysis to calculate the cumu-
lative sample size of the meta-analysis (information size) and to
reduce the risk of random errors due to sparse data and repeti-
tive testing of the accumulating data (Wetterslev 2008; Wetterslev
2009; Thorlund 2011). When conducting a meta-analysis, signif-
icance testing may be performed each time a new trial is added.
Similar to multiple interim analyses in a single clinical trial, repet-
itive testing in a meta-analysis increases the risk of type I error.
The assumption underlying Trial Sequential Analysis is that test-
ing for significance may be performed each time a new trial is
added to the meta-analysis, resulting in an increased risk of ran-
dom errors. For this reason, a statistical approach that controls the
overall risk of type I error is needed. We calculated the informa-
tion size adjusted for heterogeneity (diversity, D2) between trials
using the following parameters (Wetterslev 2009): the proportion
of events in the control group estimated from the included trials
(overall mean value); anticipated intervention effect (relative risk
reduction, RRR) of 20%; risk of type I error (α) of 0.05; power
of 0.80. We added trials to the analysis according to the year of
publication. If more than one trial was published in a year, we
added the trials in alphabetical order, according to the name of
the first author. On the basis of the required information size, we
constructed the trial sequential monitoring boundaries for ben-
efits and futility using the O’Brien-Fleming alpha spending (for
benefit) and beta-spending (for futility) functions. The boundaries
for benefit are used in case of meta-analyses that have not reached
the required information size to conclude when statistical signif-
icance is reached. If the trial sequential monitoring boundary is
crossed before the required information size is reached, a sufficient
level of evidence is reached, the results of the meta-analysis can be
considered conclusive if bias can be excluded, and no additional
trials may be needed. Conversely, if the boundary is not crossed,
the meta-analysis is inconclusive, and more trials may be needed
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in order to detect or reject a certain intervention effect. When
the cumulative Z-curve crosses the futility boundaries, a sufficient
level of evidence is reached that the two treatments do not differ
more than 20% (the anticipated intervention effect used in infor-
mation size estimation), and no additional trials may be needed.
In all situations where no trial sequential monitoring boundaries
are reached, further studies may be needed until the information
size is reached or monitoring boundaries are crossed.
We performed Trial Sequential Analysis with the Trial Sequential
Analysis software, version 0.9 beta (TSA 2011).
Subgroup analysis and investigation of heterogeneity
We considered the following for subgroup analyses.
• Sex.
• Participant age.
• Number of biliary colic attacks experienced before entry.
• Setting in which the trial was done (i.e. emergency unit or
primary, secondary, or tertiary care unit).
• Type of NSAIDs used in the trial.
• Dosage of anti-inflammatory drug used in the trial.
• Route of administration of the drug.
• Duration of follow-up.
• Risk of bias.
Sensitivity analysis
We planned no sensitivity analyses.
’Summary of findings’ table
The ’Summary of findings’ tables show the proportion of people
with lack of pain relief for the three comparisons that have been
analysed (NSAIDs versus placebo; NSAIDs versus spasmolytic
drugs; NSAIDs versus opioid drugs) and their corresponding RR
(with their 95%CI), and the proportion of people with cholelithi-
asis-related complications only for the comparison NSAIDs versus
placebo, with its corresponding RR (95% CI).
We used the GRADE system to assess the quality of evidence
and to build the ’Summary of findings’ tables for the outcomes
considered in this review. We used the GRADEpro 3.6 software
(tech.cochrane.org/revman/gradepro) to construct Summary of
findings for the main comparison, Summary of findings 2, and
Summary of findings 3. TheGRADE approach appraises the qual-
ity of a body of evidence based on the extent to which one can
be confident that an estimate of effect or association reflects the
item being assessed. The quality of a body of evidence consid-
ers within-study risk of bias, indirectness of the evidence, het-
erogeneity of the data, imprecision of effect estimates (wide CIs
and as evaluated with our Trial Sequential Analysis) (Jakobsen
2014), and risk of publication bias (Guyatt 2008; Balshem 2011;
Guyatt 2011;Guyatt 2011a;Guyatt 2011b;Guyatt 2011c;Guyatt
2011d;Guyatt 2011e;Guyatt 2011f; Guyatt 2011g;Guyatt 2013;
Mustafa 2013; Guyatt 2013a; Guyatt 2013b; Guyatt 2013c).
We defined the levels of evidence as ’high’, ’moderate’, ’low’, or
’very low’ as follows.
• High certainty: this research provides a very good
indication of the likely effect; the likelihood that the effect will
be substantially different is low.
• Moderate certainty: this research provides a good indication
of the likely effect; the likelihood that the effect will be
substantially different is moderate.
• Low certainty: this research provides some indication of the
likely effect; however, the likelihood that it will be substantially
different is high.
• Very low certainty: this research does not provide a reliable
indication of the likely effect; the likelihood that the effect will
be substantially different is very high.
R E S U L T S
Description of studies
Results of the search
We identified a total of 278 references through electronic searches
of the Cochrane Hepato-Biliary Controlled Trials Register, the
Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, Embase, and Science Citation Index Expanded un-
til 31 July 2016. We identified two publications through manual
searching. Overall, we excluded 266 references: 264 were clearly
irrelevant to the present systematic review, having read abstracts
in 258 cases and the full text of six of these publications, two
were duplicates. We have listed the six excluded studies in the
Characteristics of excluded studies table with reasons for exclu-
sion. A PRISMA flow diagram is provided in Figure 1.
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Figure 1. Flow diagram.
The remaining 12 references were reports of 12 randomised trials,
and they fulfilled our inclusion criteria. The trials included a total
of 828participants, ofwhom416 receivedNSAIDs and412 served
as controls (receiving placebo or opioids or spasmolytic drugs).
We have provided details of the included trials in Included studies.
All trials used a parallel-group design. One of the trials had three
parallel groups.
We also found one ongoing study that aims to assess the analgesic
efficacy of intravenous ibuprofen in biliary colic.
Included studies
We have provided a detailed description of the included trials in
the Characteristics of included studies table.
Trials
All of the included trials were randomised clinical trials with par-
allel-group design. In one of the included trials (Camp 1992),
NSAIDs were compared with both opioids and spasmolytic drugs.
Comparator interventions
NSAIDs versus placebo
Four trials used 50 mg to 75 mg diclofenac (Broggini 1984;
Lundstam 1985; Akriviadis 1997; Goldman 2001), and one trial
used ketoprofen versus placebo (Magrini 1985).
NSAIDs versus opioids
Three trials compared ketorolac (Dula 2001; Henderson 2002;
Olsen 2008), and one trial compared flurbiprofen with opioids
(Camp 1992).
NSAIDs versus spasmolytic drugs
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Two trials compared diclofenac (Grossi 1986; Kumar 2004), one
trial compared tenoxicam (AlWaili 1998), and one trial compared
flurbiprofen with spasmolytic drugs (hyoscine butylbromide) (
Camp 1992).
Participants
The 12 trials randomised a total of 828 people (minimum 30 and
maximum 324 per trial). Twenty-four per cent of the participants
were males.The age of participants in the trials ranged from 18 to
86 years. All participants were admitted to the emergency depart-
ment for acute biliary pain.
Age lower than 65 years represented an exclusion criteria in three
trials (Dula 2001; Henderson 2002; Olsen 2008), and the pres-
ence of co-morbidities such as diabetes mellitus, cardiovascular, or
respiratory diseases represented an exclusion criteria in one trial
(Kumar 2004). In theHenderson trial, the presence of renal insuf-
ficiency represented another exclusion criteria in addition to age
(Henderson 2002).
Comparator interventions
Five trials used placebo (Broggini 1984; Lundstam 1985; Magrini
1985; Akriviadis 1997; Goldman 2001), four trials used opioids
(Camp 1992;Dula 2001;Henderson 2002;Olsen2008), and four
trials used spasmolytic drugs in the control group (Grossi 1986;
Camp 1992; Al Waili 1998; Kumar 2004). In one of the included
trials, NSAIDs were compared with both opioids and spasmolytic
drugs (Camp 1992).
We identified one ongoing trial entitled “Analgesic efficacy of intra-
venous ibuprofen in biliary colic” by searching ClinicalTrials.gov,
which is currently recruiting participants (NCT02268955).
Excluded studies
See Characteristics of excluded studies.
We excluded six studies for the following reasons (Thornell 1979;
Niinikoski 1984; Kantor 1986; Marsala 1986: Chaudhary 1999;
Chang 2002): one study was not a randomised clinical trial
(Thornell 1979), one study compared two different types of
NSAIDs (Niinikoski 1984), one was a review (Chang 2002), one
study compared two different modalities of sodium naproxen ad-
ministration (intravenous versus intramascular) (Marsala 1986),
one used an association of NSAIDs administered together (
Chaudhary 1999), and one used NSAID for dental pain (Chang
2002).
Risk of bias in included studies
Overall, we judged all but one trial comparing NSAIDs versus
placebo to be at low risk of bias (Akriviadis 1997) (Figure 2; Figure
3).
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
We judged five trials as at low risk of bias (Akriviadis 1997; Camp
1992; Henderson 2002; Kumar 2004; Olsen 2008), and the other
seven as at unclear risk of bias for the domain allocation sequence
generation (Broggini 1984; Lundstam 1985;Magrini 1985;Grossi
1986; Goldman 2001; Al Waili 1998; Dula 2001).
Allocation concealment was adequately performed in two trials (
Akriviadis 1997; Olsen 2008), inadequately performed in one trial
(Dula 2001), and unclear in the remaining nine trials (Broggini
1984; Lundstam 1985; Magrini 1985; Grossi 1986; Camp 1992;
Al Waili 1998; Goldman 2001; Henderson 2002; Kumar 2004).
Blinding
We considered nine trials as at low risk of bias (Lundstam 1985;
Magrini 1985; Grossi 1986; Camp 1992; Akriviadis 1997; Dula
2001; Goldman 2001; Henderson 2002; Olsen 2008), and three
as at unclear risk of bias regardingboth blinding of participants and
personnel and blinding of outcome assessment (Broggini 1984; Al
Waili 1998; Kumar 2004).
Incomplete outcome data
Eleven trials were at low risk of bias (Broggini 1984; Lundstam
1985; Magrini 1985; Grossi 1986; Camp 1992; Akriviadis 1997;
Al Waili 1998; Goldman 2001; Henderson 2002; Kumar 2004;
Olsen2008), andone trial was at unclear risk of bias for incomplete
outcome data (Dula 2001).
Selective reporting
Seven trials were at low risk of bias (Camp 1992; Akriviadis 1997;
Al Waili 1998; Dula 2001; Goldman 2001; Henderson 2002;
Kumar 2004), and five trials were at unclear risk for selective out-
come reporting (Broggini 1984; Lundstam 1985; Magrini 1985;
Grossi 1986; Olsen 2008).
Other potential sources of bias
We observed no risk of for-profit bias on the side of researchers,
industries, or funding bodies, or any personal conflicts by the
authors of the trial publication in any of the included trials.
Effects of interventions
See: Summary of findings for themain comparisonNon-steroid
anti-inflammatory drugs versus placebo for biliary colic;Summary
of findings 2Non-steroid anti-inflammatory drugs versus opioids
for biliary colic; Summary of findings 3 Non-steroid anti-
inflammatory drugs versus spasmolytic drugs for biliary colic
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Primary outcomes
Mortality
No participants in the included trials died.
Lack of pain relief
The definition of ’lack of pain relief ’ differed slightly in the in-
cluded studies. However, it included:
• the need for a rescue therapy after a given period (15
minutes, 30 minutes, 1 hour, 24 hours, etc.) following NSAIDs
administration;
• inadequately subjective pain relief within a given period
following NSAIDs administration.
NSAIDs versus placebo
When compared with placebo, NSAIDs obtained a significantly
lower proportion of participants without complete pain relief (risk
ratio (RR) 0.27, 95% confidence interval (CI) 0.19 to 0.40; I2 =
0%) (Analysis 1.1).
Trial Sequential Analysis found that the required information size
was 266 participants (see details in Figure 4). The cumulative
number of participants enrolled in the trials included in this meta-
analysis was 208, corresponding to 78% of the information size.
The results of the Trial Sequential Analysis support the finding that
NSAIDs are superior to placebo in relievingpain, as the cumulative
Z-curve crossed both the conventional and the trial sequential
monitoring boundary for benefit (during the third trial in 1985)
(Figure 4). The Trial Sequential Analysis-adjusted CI was 0.17 to
0.43.
Figure 4. TSA - Lack of pain relief - NSAIDs versus placebo.Trial Sequential Analysis was performed based
on lack of complete pain relief occurrence of 78.4% in the placebo group; a relative risk reduction of 20%; a risk
of type I error of 5%; and a power of 80%. There was no diversity adjustment (D2 = 0). The resulting
information size was 266.The blue line represents the cumulative Z-score of the meta-analysis. The green-
dashed lines represent the conventional (α = 5%) boundaries for statistical significance. The two red-dashed
inward-sloping lines represent the trial sequential monitoring boundaries. The two red-dashed outward-
sloping lines represent the futility boundaries.
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NSAIDs versus opioids
We found no difference when comparing NSAIDs to opioids (dif-
ferent doses) (ketorolac, three trials (Dula 2001; Henderson 2002;
Olsen 2008); flurbiprofen, one trial (Camp 1992)) (RR0.98, 95%
CI 0.47 to 2.07; I2 = 52%) (Analysis 2.1).
Trial Sequential Analysis was performed considering an event rate
in the control group of 18%, a relative risk reduction of 20%,
risk of type I error of 5%, power of 80%, and diversity 88%. The
required information size was 13,657 participants. The number of
participants included in thismeta-analysis was 459, corresponding
to 3.4% of the information size. We did not calculate the Trial
Sequential Analysis-adjusted CI due to little information (3.4%).
NSAIDs versus spasmolytic drugs
When compared with spasmolytic drugs, NSAIDs (diclofenac,
two trials (Grossi 1986; Kumar 2004); tenoxicam, one trial (Al
Waili 1998); and flurbiprofen, one trial (Camp 1992)) showed a
significantly lower proportion of participants without complete
pain relief (RR 0.51, 95% CI 0.37 to 0.71; I2 = 0%) (Analysis
3.1).
Trial Sequential Analysis found that the required information size
was 626 participants (see details in Figure 5). The total number of
participants included in this analysis was 190 (30% of the infor-
mation size). The results of the Trial Sequential Analysis do not
support the finding thatNSAIDs are superior to spasmolytic drugs
in relieving pain, as the cumulative Z-curve did not cross the trial
sequential boundaries (Figure 5). The Trial Sequential Analysis-
adjusted CI was 0.27 to 0.98.
Figure 5. TSA - Lack of pain relief - NSAIDs versus spasmolytic drugs.Trial Sequential Analysis was
performed based on lack of complete pain relief occurrence of 56% in the spasmolytic drugs group; a relative
risk reduction of 20%; a risk of type I error of 5%; and a power of 80%. There was no diversity adjustment (D2 =
0). The resulting information size was 626.The blue line represents the cumulative Z-score of the meta-
analysis. The green-dashed lines represent the conventional (α = 5%) boundaries for statistical significance. The
two red-dashed inward-sloping lines represent the trial sequential monitoring boundaries.
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Secondary outcomes
Cholelithiasis-related complications
NSAIDs versus placebo
Three trials reported data on cholelithiasis-related complications
(Lundstam 1985; Akriviadis 1997; Goldman 2001). When com-
pared with placebo, NSAIDs showed no effect on complications
(RR 0.66, 95% CI 0.38 to 1.15; I2 = 26%) (Analysis 1.2).
Trial Sequential Analysis showed that the required information
size was 1788 participants (see details in Figure 6). The cumulative
number of participants enrolled in the trials included in this meta-
analysiswas 140, corresponding to 8%of the information size. The
cumulative Z-curve did not cross the trial sequential monitoring
boundaries. The Trial Sequential Analysis-adjusted CI was 0.07
to 6.19.
Figure 6. TSA - Cholelithiasis-related complications - NSAIDs versus placebo.Trial Sequential Analysis was
performed based on cholelithiasis-related complications occurrence of 47% in the placebo group; a relative risk
reduction of 20%; a risk of type I error of 5%; and a power of 80%; heterogeneity adjustment based on D2 =
50%. The resulting information size was 1788.The blue line represents the cumulative Z-score of the meta-
analysis. The green-dashed lines represent the conventional (α = 5%) boundaries for statistical significance. The
two pieces of red inward-sloping lines represent the trial sequential monitoring boundaries.
NSAIDs versus opioids
Only one trial comparing NSAIDs with opioids reported data on
cholelithiasis-related complications (Dula 2001), and found no
difference in the occurrence of events between the two groups
(Analysis 2.2).
As only one trial was included, we did not perform the Trial Se-
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quential Analysis. However, we attempted to estimate the required
information size (assuming a rate of events in the control group of
14%, a relative risk reduction of 20%, a risk of type I error of 5%,
a power of 80%, and a diversity of 50%), which resulted in 8820
participants. We did not calculate the Trial Sequential Analysis-
adjusted CI due to little information (0.3%).
NSAIDs versus spasmolytic drugs
Two trials reported data on cholelithiasis-related complications (Al
Waili 1998; Kumar 2004). When compared with spasmolytics,
NSAIDs showed a significantly lower proportion of disease-related
complications (RR 0.27, 95% CI 0.12 to 0.57; I2 = 0%) (Analysis
3.2).
Trial Sequential Analysis showed that the required information
size was 1800 participants (see details in Figure 7). The cumulative
number of participants enrolled in the trials included in this meta-
analysiswas 104, corresponding to 6%of the information size. The
results of the Trial Sequential Analysis do not support the finding
of the conventional meta-analysis. The cumulative Z-curve did
not cross the trial sequential monitoring boundaries (Figure 7).
The Trial Sequential Analysis-adjusted CI was 0.01 to 6.06.
Figure 7. TSA - Cholelithiasis-related complications - NSAIDs versus spasmolytic drugs.Trial Sequential
Analysis was performed based on cholelithiasis-related complications occurrence of 46% in the placebo group;
a relative risk reduction of 20%; a risk of type I error of 5%; and a power of 80%. As only two studies were
included, we used a more conservative heterogeneity adjustment based on D2 = 50% rather than data-based
diversity (D2 was 0). The resulting information size was 1800.The blue line represents the cumulative Z-score
of the meta-analysis. The green-dashed lines represent the conventional (α = 5%) boundaries for statistical
significance. The two pieces of red inward-sloping lines represent the trial sequential monitoring boundaries.
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No data were available from the trial reports concerning either the
risk of bleeding after an operative intervention or after an ERCP
procedure.
Major bleeding was defined as a reduction in the haemoglobin
level of at least 20 grams per litre, transfusion of at least 2 units of
blood, or symptomatic bleeding.
Life-threatening bleeding was a subcategory of major bleeding
that consisted of fatal bleeding, symptomatic intracranial bleeding,
bleeding with a decrease in the haemoglobin level of at least 50
grams per litre, or bleeding requiring transfusion of at least 4 units
of blood or inotropic agents or necessitating surgery.
Quality of life
None of the included trials assessed quality of life.
Drug-related complications and adverse events, expressed as
the number of participants experiencing these events
None of the 12 included trials reported severe adverse events.
Seven out of the 12 trials assessed non-severe adverse events; in
two out of the seven trials no adverse events were observed. In
the trial by Camp and colleagues (Camp 1992), some mild ad-
verse events were reported. Among the 30 participants on flur-
biprofen, one participant had fever and one experienced anxiety;
among the 25 participants on hyoscine butylbromide one had
headache, one nausea, one dry mouth, and one tachycardia; and
among the 29 participants on pentazocine, six had nausea, four
vomiting, one dry mouth, and five dizziness. In the trial by Grossi
and colleagues (Grossi 1986), no participants on diclofenac or
hyoscine butylbromide experienced adverse events. However, di-
clofenac and hyoscine butylbromide caused a significant decrease
in systolic blood pressure. In the trial by Henderson and col-
leagues (Henderson 2002), drowsiness was the most frequent ad-
verse event, observed in 34.6% of the 175 participants treated
with ketorolac and 42.1% of the 149 participants treated with
pethidine. Nausea and dizziness were significantly more frequent
in the pethidine group than in the ketorolac group (16.4% versus
6.8% and 17.9%versus 6.8%). In the trial byOlsen and colleagues
(Olsen 2008), the proportion of participants experiencing nausea
(24% versus 4%), vomiting (5% versus 0%), and rash (0% versus
4%) did not differ significantly between the ketorolac group and
the butorphanol group, whereas the proportion of participants
experiencing sedation (5% versus 36%) and dizziness (0% versus
28%) was significantly higher in the butorphanol group as com-
pared to ketorolac group. In the trial by Lunstam and colleagues
(Lundstam 1985), only significant decrease in systolic blood pres-
sure was observed in both groups (diclofenac or placebo). In the
trial by Magrini and colleagues (Magrini 1985), blood pressure
was moderately but significantly decreased in the two treatment
groups (ketoprofen or lysine acetyl salicylate), while this was not
observed in the placebo group.
Meta-analyses of the quantification of pain relief were not possible
as the included trials used different scoring scales, and pain was
assessed at different time points after the intervention. Also, the
definition of the timespan to obtain pain relief was very hetero-
geneous among trials, preventing any possible comparison among
patient groups.
Quantification of pain relief
In most of the included trials quantification of pain relief was
assessed using different visual analogue scales (VAS), precluding
any possible comparisons among trial participant groups.
Broggini 1984 assessed the severity of pain used a three-point scale
(1 = no relief, 2 = partial relief, 3 = complete relief ) every 5 min-
utes up to 25 minutes after drug injection. Lundstam 1985 used a
similar approach, assessing pain intensity after 15 and 30 minutes
after the drug injection. Dula 2001 rated pain severity according
to a four-point scale (0 = no effective, 1 =mildly effective, 2 =mod-
erately effective, 3= completely effective) before and 30 minutes
after injection of medication. In Henderson 2002, pain severity
was graded on a four-point categorical scale (0 = no pain, 1 =mild,
2 = moderate, 3= severe), and mean VAS for the two treatment
groups were compared after 30 minutes, 1 and 2 hours after drug
injection. Camp 1992 used a four-point semi-quantitative scale to
quantify pain severity (0 = no pain, 1 = mild, 2 = moderate, 3 =
severe), and the evolution of pain was checked every hour until 6
hours after drug injection. Magrini 1985 used a five-point scale (0
= no pain, 1 = mild, 2 = moderate, 3 = severe; 4 = very severe), but
pain intensity was assessed at 15, 30, 60, and 120 minutes after
drug injection. In Akriviadis 1997, response of pain to treatment
was defined as no response (same or worse grade), improvement
(amelioration of pain by at least one grade), or relief. The severity
of pain was graded according to a four-point scale (0 = absent, 1 =
mild, 2 =moderate, and 3 = severe requiring analgesia). Sequential
assessment for response of pain to treatment was performed every
15 minutes for the first 120 minutes and every 60 minutes for
the first 8 hours after drug administration. In Al Waili 1998, a
five-point categorical scale (0 = no pain, 1 = mild, 2 = moderate,
3 = severe, 4 = very severe) was used and mean VAS recorded at
30 and 60 minutes after drug administration. In Kumar 2004,
pain severity was recorded on a 10-point VAS and checked at 30
minutes, 1, 2, and 4 hours after drug injection. Olsen 2008 used
a 10-point faces numerical pain scale (1 minimal pain, 10 max-
imal) and assessed pain intensity 15 and 30 minutes after drug
administration. In Goldman 2001, the severity of pain was rated
on an A-to-D scale (A = mild pain; D = intractable pain) every
10 to 15 minutes. Grossi 1986 assessed the intensity of pain at 30
and 60 minutes after medication injection using a 100-millimetre
analogue chromatic scale (0 mm = no pain, 100 mm = unbearable
pain). Differences in the scales used for rating pain were accounted
for by multiplying by 10 for the 10-point scale, by 20 for the five-
point scale, and by 25 for the four-point scale. We left unchanged
scales in which pain was rated on a 100-millimetre analogue chro-
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matic rating system (data synthesis or extraction).
In Broggini 1984, mean pain intensity changed 25 minutes after
the injection on the VAS, from 80 mm to 9 mm in the diclofenac
group and from 85 mm to 86 mm in the placebo group.
Lundstam 1985 observed that pain estimated on the VAS was
reduced by 58% in the diclofenac group and 39% in the placebo
group.
Dula 2001 observed that pain relief at 30 minutes was 3.8 ± 2.6
in the ketorolac group and 3.9 ± 2.5 in the pethidine group, a
difference that was not statistically significant.
In Henderson 2002, no significant differences in mean VAS val-
ues were found between groups at two hours after drug injection
(ketorolac versus pethidine).
In Camp 1992, participants receiving ibuprofen showed signifi-
cantly lower mean pain intensity VAS values compared to those
receiving pentazocine or hyoscine butylbromide .
InMagrini 1985, total pain score andVAS valueswere significantly
lower at each time point in the ketoprofen group as compared to
placebo.
In Akriviadis 1997, response of pain to treatment was defined as
no response (same or worse grade), improvement (amelioration of
pain by at least one grade), or relief. No data were available regard-
ing pain quantification and its modification over time (Akriviadis
1997).
In Al Waili 1998, mean pain score in the tenoxicam group de-
creased from 2.75 ± 0.9 to 0.49 ± 0.51 at 30 minutes and to 0.58
± 0.57 at 60 minutes; in the hyoscine butylbromide group pain
decreased from 2.62 ± 1.0 to 0.57 ± 0.5 at 30 minutes and to 0.66
± 0.5 at 60 minutes.
In Kumar 2004, at 2 hours from injection, pain severity in the
diclofenac group decreased from 9.5 ± 0.54 to 0.62 ± 0.83, and
in the hyoscine group it decreased from 9.6 ± 0.48 to 1.69 ± 1.0.
In Goldman 2001, severity of pain was rated on an A-to-D scale
(A = mild pain; D = intractable pain) every 10 to 15 minutes.
No data were available on the quantification of pain, but average
response time lapse was shortest in the diclofenac group (15 min-
utes) as compared to placebo (35 minutes) and papaverine group
(20 minutes).
Grossi 1986 observed the course of pain intensity over the 60min-
utes after injection, showing that all three of the drugs studiedwere
effective in relieving pain, however the diclofenac group showed a
significantly higher reduction in mean pain score as compared to
the glucagon and hyoscine butylbromide groups.
The time needed to obtain pain relief
Most of the included trials reported the time needed to obtain
pain relief only as a descriptive variable. Most of the trials assessed
participants at predefined time intervals, ranging from 25minutes
up to 3 hours (see data reported in theMethods section and in the
previous paragraph).
Subgroup analyses
Itwas not possible to conduct any of the planned subgroup analyses
due to the low number of trials and the lack of data regarding the
predefined variables.
Sensitivity analysis
We planned no sensitivity analysis.
Adverse events reported in non-randomised studies
Our search was primarily aimed at identifying randomised clinical
trials. However, we retrieved from the searches several citations
from quasi- or non-randomised studies. We searched for adverse
events in these studies, but were unable to find any specific adverse
events.
Publication bias
It was not possible to create a funnel plot to assess publication bias
as the number of trials in each of the four meta-analyses was less
than 10.
GRADE assessments
We rated the quality of evidence for two of the primary outcomes,
lack of pain relief and cholelithiasis-related complications, in the
’Summary of findings’ tables. We performed the assessment of
these outcomes for the three analysed comparisons in separate:
NSAIDs versus placebo; NSAIDs versus opioids; and NSAIDs
versus spasmolytic drugs. For the comparison NSAIDs versus
placebo, we graded the overall quality low for ’lack of pain relief ’
and very low for ’cholelithiasis-related complications’ (Summary
of findings for the main comparison); for NSAIDs versus opioids,
we graded the overall quality very low for both ’lack of pain relief ’
and ’cholelithiasis-related complications’ (Summary of findings 2);
and for NSAIDs versus spasmolytic drugs, we graded the overall
quality low for both ’lack of pain relief ’ and ’cholelithiasis-related
complications’ (Summary of findings 3).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Non-steroid anti- inflammatory drugs versus opioids for biliary colic
Patient or population: people with biliary colic
Settings: emergency departments
Intervention: NSAIDs versus opioids
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control NSAIDs versus opioids
Lack of pain relief Study population RR 0.98
(0.47 to 2.07)
459
(4 studies)
⊕©©©
very low1,2
180 per 1000 176 per 1000
(84 to 372)
M oderate
203 per 1000 199 per 1000
(95 to 420)
Cholelithiasis- related
complications
Study population RR 0.88
(0.14 to 5.42)
30
(1 study)
⊕©©©
very low2,3
143 per 1000 126 per 1000
(20 to 774)
M oderate
143 per 1000 126 per 1000
(20 to 775)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; NSAIDs: non-steroid ant i-inf lammatory drugs; RR: risk rat io21
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded one level (-1) for risk of bias because the overall risk of bias was unclear in three and high in one out of four
studies.
2Downgraded two levels (-2) for imprecision: wide 95% CI including appreciable benef its and harms (RR < 0.75 and RR > 1.25);
the required information size was not reached.
3Downgraded one level (-1) for risk of bias because of only one study which is also at overall high risk of bias.
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Non-steroid anti- inflammatory drugs versus spasmolytic drugs for biliary colic
Patient or population: people with biliary colic
Settings: emergency departments
Intervention: NSAIDs versus spasmolyt ic drugs
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control NSAIDs versus spas-
molytic drugs
Lack of pain relief Study population RR 0.51
(0.37 to 0.71)
190
(4 studies)
⊕⊕©©
low1,2
598 per 1000 305 per 1000
(221 to 424)
M oderate
615 per 1000 314 per 1000
(228 to 437)
Cholelithiasis- related
complications
Study population RR 0.27
(0.12 to 0.57)
104
(2 studies)
⊕⊕©©
low1,2
462 per 1000 125 per 1000
(55 to 263)
M oderate
420 per 1000 113 per 1000
(50 to 239)
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: conf idence interval; NSAIDs: non-steroid ant i-inf lammatory drugs; RR: risk rat io23
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded one level (-1) for risk of bias because the overall risk of bias was unclear in all the studies.
2Downgraded one level (-1) for imprecision: the required information size was not reached.
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D I S C U S S I O N
Summary of main results
Twelve randomised clinical trials assessed the use of NSAIDs in
people attending emergency departments with symptoms of bil-
iary colic. Our traditional meta-analysis showed NSAIDs to be
effective in relieving pain by significantly reducing the number
of participants without complete pain relief in comparison to
placebo or spasmolytic drugs. However, Trial Sequential Analy-
sis confirmed only the result obtained when comparing NSAIDs
with placebo. The trials comparing NSAIDs and opioids failed to
demonstrate a significant difference; however, present data are not
able to definitively support equivalence in pain relief between these
two classes of drugs. Moreover, NSAIDs significantly reduced the
proportion of short-term complications such as acute cholecysti-
tis, jaundice, cholangitis, and acute pancreatitis when compared
with spasmolytics, but not when compared with placebo. This
effect may be due either to a beneficial effect of NSAIDs or to a
harmful effect of spasmolytic drugs, however the latter could not
be currently determined.
Five trials tested diclofenac 50 mg to 75 mg intramuscularly (i.m.)
and ketoprofen 200mg intravenously (i.v.) against placebo (saline)
with consistent results demonstrating a superior analgesic efficacy
of these two NSAIDs. This result was confirmed by the Trial Se-
quential Analysis. However, the comparison betweenNSAIDs and
other commonly used drugs (spasmolytic and opioid) seems more
relevant.
Hyoscine butylbromide (also known as scopolamine) is an anti-
cholinergic drug, commonly used because of its presumed spas-
molytic activity. We found four randomised clinical trials compar-
ing NSAIDs and hyoscine butylbromide that consistently and sig-
nificantly demonstrated a more effective pain relief with NSAIDs
(diclofenac 75 mg i.m., tenoxicam 20 mg i.v., and flurbiprofen
150 mg i.m.) than the spasmolytic drugs (hyoscine butylbromide
20 mg i.v. or i.m., hyoscine butylbromide 20 mg i.m). In one trial,
glucagon (1 mg i.m.) was as effective as diclofenac (75 mg i.m)
for obtaining pain relief (Grossi 1986). However, glucagon is no
longer used due to its adverse effects. Due to their well-known
analgesic effect, pethidine and pentazocine are commonly used, in
particular because they prevent the sphincter of Oddi spasm asso-
ciated with use of the other opioids. However, the Trial Sequential
Analysis did not support the finding of the conventional meta-
analysis, suggesting that firm evidence has not yet been reached.
Only four trials comparedNSAIDs versus opioids (twowith pethi-
dine, one with pentazocine, and one with butorphanol) including
about 242 and 217 participants in each group. The results for
this comparison showed significant statistical heterogeneity, and
no difference in the analgesic effect was observed between the two
drugs. A possible explanation for the inconsistency of data could
be related to the different drugs used, route of administration, and
time of pain assessment. In particular, the largest trial by Hender-
son (Henderson 2002) used pethidine 50 mg intravenously and
assessed pain after 1 hour, whereas the other three smaller trials
used pentazocine or pethidine intramuscularly and assessed pain
earlier, at 30 minutes. The present data do not allow us to reject
the null hypothesis, as they are underpowered. Also in this analy-
sis, the Trial Sequential Analysis did not support the result of the
meta-analysis, implying that firm evidence was not reached.
The percentage of participants with biliary colic who developed
cholelithiasis-related complications such as cholecystitis, or less
frequently choledocholithiasis, cholangitis, or gallstone pancreati-
tis, varied. Our results indicate that NSAIDs were not able to
reduce the rate of short-term complications of biliary colic in
comparison with placebo; we observed a reduction in the rate
of cholelithiasis-related complications in comparison with spas-
molytic drugs, even if this result was not confirmed by Trial Se-
quential Analysis.
The interpretation of our findings regarding cholelithiasis-related
complications is difficult and should be considered with caution.
In fact, the studies included in the two analyses (NSAIDs versus
placebo and NSAIDs versus spasmolytic drugs) are very differ-
ent. For example, there was a higher rate of complications in the
treatment arm of trials included in the former analysis (29%) as
compared to the latter analysis (11%). This is likely a consequence
of different participant selection with varying disease severity and
probably for different definitions of complications. In only one
trial, comparing NSAIDs versus placebo, were cholelithiasis-re-
lated complications assessed and separately reported according to
clearly predefined criteria (Akriviadis 1997). In two other trials,
comparing NSAIDs versus placebo (Lundstam 1985; Goldman
2001), and in two trials comparing NSAIDs versus spasmolytics
(Al Waili 1998; Kumar 2004), only the rate of clinically evident
cholecystitis was recorded. In addition, when exclusion criteria
were stricter in some of the trials (Al Waili 1998; Dula 2001),
incidences of complications were lower. People with diabetes or
other systemic comorbidities and people older than 65 years were
excluded from all trials, apart from Akriviadis 1997. These people
can be regarded as a subgroup in which complications related to
cholelithiasis are more frequent and severe (Kimura 2007).
The above concept applies also for adverse events related to
NSAIDs. In most of the included trials, data collection about ad-
verse drug effects was neither planned nor reported. These limi-
tations prevent clear and definitive assessment of the benefits and
harms of the use of NSAIDs just in the subgroup of participants
with higher risk of severe complications, particularly in compar-
ison to pethidine, which shows at least similar analgesic activity
(Dula 2001; Henderson 2002).
There was no clear difference in the reported number or severity
of adverse effects between the different types of NSAIDs in the
trials included in this review. Several articles have reported on
the adverse effects of NSAIDs, especially gastrointestinal events.
Adverse effects that were more frequently reported in the trials
presented in this review included nausea, dry mouth, abdominal
pain, diarrhoea, oedema, decrease in systolic blood pressure, rash,
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dizziness, headache, tiredness, fever, and anxiety.
The authors of the included trials considered most adverse effects
to be mild to moderate. However, as the sample sizes of most of
the studies were relatively small, no clear conclusion can be drawn
regarding the risks for gastrointestinal and other adverse effects of
NSAIDs.
Regarding the possible onset of cardiovascular adverse effects, apart
from a transitory decrease in systolic blood pressure, these were
not reported in the trials included in our present review. How-
ever, it must be noted that cardiovascular adverse events are more
common with the use of cyclooxygenase 2 (COX-2) inhibitor
drugs than with classical NSAIDs, and that the use of NSAIDs
can be considered to be relatively safe when prescribed at the most
effective dose and for the shortest period of time (Aminoshariae
2016). Indeed, in the trials included in the present systematic re-
view, NSAIDs were used for a very short period of time, and in all
cases for less than 10 days.
None of the included trials reported data on the possible associa-
tion between NSAIDs use and increased risk of bleeding after sur-
gical or endoscopic procedures for cholelithiasis-related complica-
tions. In a recent meta-analysis of rectal NSAIDs in the prevention
of post-ERCP pancreatitis, the risk of bleeding seems not to be
increased (Elmunzer 2008). Interestingly, NSAIDs are effective in
the prevention of post-ERCP pancreatitis, and this may further
support our findings of a low proportion of cholelithiasis-related
complications, probably related to inhibition of prostaglandin,
phospholipase A2, and neutrophil-endothelial interactions, all of
which are involved in their pathogenesis (Zheng 2008).
We also found one ongoing randomised clinical trial that aims
to assess the analgesic efficacy of intravenous ibuprofen in biliary
colic.
Overall completeness and applicability of
evidence
This systematic review examined the evidence from12 randomised
trials comparingNSAIDs versus no intervention, placebo, or other
drugs in people attending emergency departments with symptoms
of biliary colic. These trials included all people presenting with
biliary colic according to the definitions and diagnostic work-up
in the individual trials.
All trials reported on the primary outcomes of mortality, (lack of )
complete pain relief, and number of participants with cholelithi-
asis-related complications, whereas in most of the included trials
no data were available regarding drug-related complications and
adverse events, and most of the remaining secondary outcomes
such as risk of bleeding after surgical or endoscopic procedures,
quality of life, quantification of pain relief, and time to obtain pain
relief.
In addition, when exclusion criteria were stricter in some of the
trials (Al Waili 1998; Dula 2001), incidences of complications
were lower. People with diabetes or other systemic comorbidities
or whowere older than 65 years were excluded from all trials, apart
from Akriviadis 1997. These people can be regarded as a subgroup
in which complications related to cholelithiasis are more frequent
and severe (Kimura 2007).
Quality of the evidence
We conducted our review following the recommendations of the
Cochrane Handbook for Systematic Reviews of Interventions and the
Cochrane Hepato-Biliary Group (Higgins 2011; Gluud 2016).
The findings of our review and the quality of the evidence are
affected by the quality of the primary trials included in the review.
We found only one trial to be at low risk of bias for all the quality
domains considered. We considered most of the trials to be at
unclear risk of bias for at least two quality domains, and only one
trial to be at high risk of bias for at least one quality domain. In
particular, wemore frequently observed risk of bias for the random
sequence generation and allocation concealment domains, both
of which reflect the presence of a selection bias.
However, for trials classified as at unclear risk of bias, we cannot
exclude the presence of high risk of bias.
We also performed Trial Sequential Analysis to deal with the risks
of random errors and to prevent premature declaration of superi-
ority of NSAIDs (Wetterslev 2009). According to these analyses,
systematic errors may still influence the results of a number of
comparisons in our review.
Regarding GRADE assessments, we rated none of the trials as
providing strong evidence, primarily because of the presence of
risk of bias, the required information size was not reached, and
imprecision of pooled estimates.
Overall, we did not observe relevant heterogeneity among the stud-
ies apart from exclusion criteria differing in some of them, for ex-
ample the exclusion of participants older than 65 years or of those
with comorbidities such as diabetes, or a different definition of
complications.
The presence of a possible publication bias cannot be excluded as
a formal analysis was prevented by the small number of studies.
Potential biases in the review process
We attempted to minimise the risk of bias in the review process by
strictly following Cochrane’s methodology during the preparation
of our review.
We performed an exhaustive bibliographic search, and two review
authors extracted data independently. Although the search strat-
egy was very sensitive, due to the low number of included trials
we could not test for funnel plot asymmetry to assess the risk of
publication bias. This is a clear limitation of our review.
The quality of the primary trials included in our review is, as usual,
a limiting factor for the strength of the evidence of our results.
Agreements and disagreements with other
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studies or reviews
With respect to the two non-Cochrane systematic reviews already
published (BasurtoOna 2008; Colli 2012), somemain differences
should be underlined.
The earliest-dated review is a Spanish review that does not com-
pare NSAIDs versus placebo or other drugs for biliary colic in
people with cholelithiasis (Basurto Ona 2008). The authors con-
cluded that NSAIDs are the first drugs that should be used in
people with uncomplicated biliary colic, as they found a signif-
icantly higher analgesic effect and a better prognosis (lower rate
of progression to acute cholecystitis) for NSAIDs as compared to
’other drugs’, which, differing from the present review, they con-
sidered to be a heterogeneous group of drugs. Basurto Ona 2008
included only seven randomised clinical trials that enrolled 349
participants (Niinikoski 1984; Grossi 1986; Camp 1992; AlWaili
1998; Dula 2001; Goldman 2001; Kumar 2004). We included
all of these studies, apart from one that we excluded as it com-
pares two NSAIDs (indomethacin 50 mg versus metamizole 2.5
g) (Niinikoski 1984), in our own review.
Our own group published the other non-Cochrane review (Colli
2012). In this review, we did not rate the overall evidence and
did not perform a Trial Sequential Analysis to calculate the cu-
mulative sample size of the meta-analysis (information size), thus
overestimating the efficacy of NSAIDs in reducing biliary colic
complications.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Our results indicate that NSAIDs control pain better than placebo
and spasmolytic drugs in people with biliary colic. However, only
one randomised clinical trial was at low risk of bias.
We found limited evidence that NSAIDs reduce cholelithiasis-
related complications. Regarding the reduced risk of cholelithia-
sis-related complications observed for NSAIDs versus spasmolytic
drugs, the evidence is provided by only two trials including 104
participants. In addition, it is unclear whether this finding is re-
lated to the beneficial effect of NSAIDs or to a harmful effect of
spasmolytics.
Furthermore, regarding the presence of complications, a limitation
of the present systematic review is that its generalisability is low
as most of the randomised clinical trials did not include elderly
people or people with co-morbidities, or both, who aremore prone
to complication as compared to other included participants.
None of the trials provided information on quality of life, and
information on adverse events remains unclear.
Implications for research
We need more evidence with appropriately sized randomised clin-
ical trials at low risk of bias before we can draw any firm con-
clusions on the effect of NSAIDs in pain control for people with
biliary colic.
The lack of data regarding people with a wider spectrum of age or
with co-morbidities (e.g. diabetes, etc.), or both, actually repre-
senting the subgroup with a higher proportion of severe gallstone-
related complications, makes the conclusions of this review not
completely generalisable, indicating a need for new trials with less
stringent inclusion criteria.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Akriviadis 1997
Methods Randomised clinical trial with parallel-group design
Participants People with right upper quadrant or epigastric pain seen in a Greek emergency depart-
ment
The presence of gallstones was documented at ultrasonography. Criteria for exclusion:
temperature > 37.5 °C, jaundice, sign of peritoneal irritation, microscopic haematuria,
previous use of analgesics or antibiotic within 8 hours of enrolment, increase of serum
amylases, history of peptic ulcer disease
81 people were considered for the enrolment. 28 people were excluded as they did not
meet the inclusion criteria
Interventions Group 1: diclofenac, single 75 mg, 3 mL intramuscular injection (27 participants)
Group 2: saline, 3 mL intramuscular injection (26 participants)
All enrolled participants were admitted to the wards for a minimum of 3 days. Sequential
assessment of pain response to treatment was performed every 15 minutes for the first
120minutes, and then every 60minutes for 8 hours. All participants were given analgesic
rescue therapy with propoxyphene hydrochloride 2 hours after the initiation of the trial
Outcomes Lack of complete pain relief was observed in 6 out of 27 participants in the diclofenac
group versus 19 out of 26 in the placebo group. Gallstone-related complications, assessed
according to predefined criteria, were significantly lower in participants in diclofenac
group (13/27) than in the placebo group (21/26). Authors stated that they did not find
any adverse reaction to diclofenac or placebo, even if systematically searched
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random allocation was performed using
a random number table”
Allocation concealment (selection bias) Low risk “The sealed-opaque envelope method was
used to conceal allocation concealment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk The trial protocol is available, and all of
the trial’s prespecified outcomes that are of
interest in the review have been reported
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Akriviadis 1997 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk 3 mL of diclofenac (containing 75 mg of
active principle) or 3 mL of saline were pre-
pared by the pharmacist and taken to the
ward to be injected. Charting of the type of
injection given was done by the pharmacist
As diclofenac was slightly yellow in colour,
masking of the participant was achieved by
carrying the syringe with medication in a
wrapped bag that was opened immediately
before the injection in order that the par-
ticipant could not see the syringe
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The outcome assessment was performed
by the same physician/personnel who ad-
ministered treatment”
Other bias Low risk There was no statement on conflict of in-
terest.
Al Waili 1998
Methods Randomised clinical trial with parallel-group design
Participants 32 participants (26 women and 6 men, mean age 47 years) presenting with acute biliary
colic diagnosed on the basis of physical examination, laboratory test, liver and renal
function test, serum electrolytes, serum amylases, and ultrasonography were enrolled
Included participants were seen at the emergency department within 2 hours of onset
from their symptoms. Occurrence and severity of pain were rated on a 5-point scale: 0 =
no pain; 1= mild pain; 2 = moderate pain; 3 = severe pain; 4 = very severe pain. Methods
of random allocation were not detailed
People who had received spasmolytic, pethidine, or any prostaglandin synthesis inhibitor
within 2 hours were excluded from the trial, as well as those who had jaundice, liver
or renal impairment, cardiovascular disease, acute cholecystitis, or history of allergy to
other NSAIDs
Pain severity and relief were recorded on a scale at 15-minute intervals for up to 1 hour,
and then hourly for 12 hours
Interventions Group 1: tenoxicam, 20 mg i.v. (16 participants).
Group 2: hyoscine N-butylbromide, 20 mg i.v. (16 participants)
For both groups, an analgesic rescue therapy was planned after 1 hour with pethidine
(100 mg i.v.)
Outcomes Lack of complete pain relief within 30 minutes from injection was observed in 6 out of
16 participants in the tenoxicam group versus 9 out of 16 participants in the hyoscine
group
In the tenoxicam group, pre-treatment mean pain score was 2.75 ± 0.93 and decreased
to 0.49 ± 0.51 within 30 minutes. In the hyoscine group, the mean pain score was 2.62
± 1.01 and decreased to 0.57 ± 0.53 within 30 minutes
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Al Waili 1998 (Continued)
No participant on tenoxicam showed complications, whereas 5 participants in the
hyoscine group developed acute cholecystitis according to clinical criteria
Drug-related adverse events were not observed in the trial.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear
Allocation concealment (selection bias) Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk The trial protocol is available, and all of
the trial’s prespecified outcomes that are of
interest in the review have been reported or
similar
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information given.
Other bias Low risk No risk of for-profit bias on the side of re-
searchers, manufacturers, or funding bod-
ies or any personal conflicts by the authors
of the trial publication were observed
Broggini 1984
Methods Randomised clinical trial with parallel-group design
Participants 30 consecutive outpatients (14 men and 16 women, mean age 46 years) with gallstones
demonstrated at ultrasonography, radiography, or at operation andpresentingwith biliary
colic
Interventions Group 1: diclofenac sodium, 75 mg intramuscularly (14 participants)
Group 2: saline (16 participants)
Participants were randomised (methods of random allocation not detailed) to receive
75 mg of diclofenac i.m. (14 participants) or placebo (16 participants) and followed up
for 24 hours. The 2 patient groups were similar regarding age, sex, weight, duration of
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Broggini 1984 (Continued)
pain, and initial intensity of pain. Before the injection and 25 minutes afterwards, the
intensity of pain was recorded on a scale where 0 represents no pain and 100 unbearable
pain
Outcomes After 25 minutes, lack of complete pain relief was observed in 5 out of 14 participants in
the diclofenac group versus 16 out of 16 participants in the placebo group. Mean pain
intensity changed from 80.2 ± 13.07 to 9.7 ± 8.78 in the diclofenac group and from 85.
7 ± 9.53 to 86.0 ± 9.87 in the placebo group
Cholelithiasis-related complications were not observed and reported
No side effects were observed and reported in the 2 groups.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear
Allocation concealment (selection bias) Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Unclear risk There is insufficient information to assess
whether themagnitude and direction of the
observed effect is related to selective out-
come reporting
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information given.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information given.
Other bias Low risk No risk of for-profit bias on the side of re-
searchers, manufacturers, or funding bod-
ies or any personal conflicts by the authors
of the trial publication were observed
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Camp 1992
Methods Randomised clinical trial with parallel-group design
Participants The trial included 84 people with biliary colic, presenting at emergency department
Exclusion criteria were acute cholecystitis, pancreatitis, renal colic, hepatic or renal dis-
ease, peptic ulcer, ischaemic heart disease, and glaucoma
Interventions Participants were allocated to 3 groups:
Group 1: flurbiprofen 150 mg i.m. (30 participants)
Group 2: hyoscine 20 mg i.m. (25 participants)
Group 3: pentazocine 30 mg i.m. (29 participants)
An analgesic rescue therapy was planned. Participants were followed up for 6 hours after
treatment
Outcomes Lack of pain relief was observed in 2 out of 30 participants with flurbiprofen, 7 out of
25 participants with hyoscine, and 6 out 29 participants with pentazocine. Side effects
in the flurbiprofen group were: fever (1 participant) and anxiety (1 participant); in the
hyoscine group headache (1), nausea (1), dry mouth (1), and tachycardia (1 case); and
in the pentazocine group: nausea (6) vomiting (4), dry mouth (1), dizziness (5)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random allocation was performed using
computer-generated sequences
Allocation concealment (selection bias) Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk The trial protocol is available and all of the
trial’s prespecified outcomes that are of in-
terest in the review have been reported or
similar
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The person who administered the treat-
ment was different from the one who took
care of the patient
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome assessment was performed by
the same physician/personnel who admin-
istered treatment
Other bias Low risk No risk of for-profit bias on the side of re-
searchers, manufacturers, or funding bod-
ies or any personal conflicts by the authors
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Camp 1992 (Continued)
of the trial publication were observed
Dula 2001
Methods Randomised clinical trial with parallel-group design
Participants The trial enrolled participants presenting at the emergency department with symptoms
consistent with biliary colic and diagnosis confirmed by abdominal ultrasound
Exclusion criteria: age less than 18 years or greater than 65 years, person’s rectal temper-
ature > 38 °C, previous allergy to ketorolac or other NSAIDs or previous adverse reac-
tions to pethidine, pregnancy, history of renal disease, or ongoing oral anticoagulation.
Enrolment was not consecutive
30 participants were enrolled in the trial: 16 in the ketorolac group (mean age 42.5 ± 14.
3 years; 19% males) and 14 in the pethidine group (mean age 40.6 ± 14.3 years; 21%
males)
Interventions Group 1: ketorolac 60 mg i.m. (16 participants)
Group 2: pethidine 1.5 mg/kg i.m. (14 participants) with a maximum of 100 mg
In all groups a rescue therapy was predefined, with pethidine 1 mg/kg i.m. after 30
minutes
10-point VAS (1 to 10) was used to score pain, before and 30 minutes after treatment
Before discharge, participants were asked to complete a questionnaire to rate the effec-
tiveness of treatment (0 = no effective; 1= mildly effective; 2 = moderately effective; 3 =
completely effective)
Outcomes The average pain score was 7.6 ± 1.9 for the ketorolac group and 7.3 ± 2.4 for the
pethidine group. 30 minutes after treatment pain score decreased to 3.8 ± 2.6 for the
ketorolac group and 3.9 ± 2.5 for the pethidine group
Regarding complications, the need for emergency cholecystectomy was also assessed. In
the 2-week follow-up period this was performed in 2 participants in the pethidine group
and 2 participants in the ketorolac group
Information on adverse events was not reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear
Allocation concealment (selection bias) High risk Enrollment was not consecutive
When a trial patient was identified, the
emergency department nurse was in-
structed to refer to a posted randomised
schedule in order to assign a patient into a
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Dula 2001 (Continued)
treatment group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear. No missing outcome data.
Selective reporting (reporting bias) Low risk The trial protocol is available and all of the
trial’s prespecified outcomes that are of in-
terest in the review have been reported or
similar
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The physician and the patient were blinded
because both medications were given i.m.
and only the nurse knew the identity of the
medication administered
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome assessment was performed by
the same physician/personnel who admin-
istered treatment
Other bias Low risk No risk of for-profit bias on the side of re-
searchers, manufacturers, or funding bod-
ies or any personal conflicts by the authors
of the trial publication were observed
Goldman 2001
Methods Randomised clinical trial with parallel-group design
Participants The trial included 60 participants admitted to the emergency ward with biliary colic
with gallstones demonstrated by ultrasonography performed in the previous 6 months
or at the emergency ward
Participants in this trial were divided into 3 groups. A fourth group of participants with
low back pain was included for comparative purposes
Group 1: average age 61 years; 12 females and 8 males
Group 2: average age 58 years; 14 females and 6 males
Group 3: average age 65 years; 10 females and 10 males
Group 4: average age 52 years; 8 females and 12 males
Exclusion criteria: temperature > 37.5 °C, signs of peritoneal inflammation, white blood
count > 10.000/mm3 or serum amylases over the normal limit, history of peptic disease,
or hypersensitivity to diclofenac
Severity of pain was rated on a scale of A to D (A = mild pain; D = intractable pain)
Response to drug administration was defined as: no response, improvement, or relief
of pain. Inquiry as to severity of pain was done every 10 to 15 min by the attending
internist
Time lapse for the onset of the drug’s alleviating effect and levels of responsewere recorded
for each group
All participants remained in emergency ward for a period of 24 hours
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Goldman 2001 (Continued)
Interventions Group 1: placebo (3 mL of normal saline, i.m ) (20 participants)
Group 2: papaverine 80 mg i.m. injection (20 participants)
Group 3: diclofenac 75 mg i.m. injection (20 participants)
Group 4: diclofenac 75 mg i.m. injection (20 participants with low back pain)
Only group 1 and group 3 were considered in this review.
Outcomes 15 participants in the placebo group and 13 participants receiving papaverine had no
improvement versus only 1 of those receiving diclofenac. On the other hand, of the
participants receiving diclofenac, 17 responded with complete pain relief, 2 with par-
tial improvement, and only 1 participant failed to respond. 5 participants treated with
placebo and 4 with papaverine needed hospitalisation; all 9 of these participants pro-
gressed to acute cholecystitis. None of the participants administered diclofenac required
hospitalisation or surgery within the period of observation
Group 4, which included participants with low back pain who received diclofenac,
showed pain relief in 5 participants (25%), improvement in 7 participants (35%), and
no response in the remaining 8 participants (40%). The trial did not report data on
adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear
Allocation concealment (selection bias) Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk The trial protocol is available, and all of
the trial’s prespecified outcomes that are of
interest in the review have been reported or
similar
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Neither the participants nor the attending
intern were aware of the type of drug ad-
ministered
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome assessment was performed by
the same physician/personnel who admin-
istered treatment
Other bias Low risk No risk of for-profit bias on the side of re-
searchers, manufacturers, or funding bod-
ies or any personal conflicts by the authors
of the trial publication were observed
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Grossi 1986
Methods Randomised clinical trial with parallel-group design
Participants The trial included 54 participants presenting at the emergency department for biliary
colic; diagnosis was confirmed by ultrasonography
Exclusion criteria: hypersensitivity to NSAIDs, peptic ulcer, and bronchial asthma
Interventions Participants were randomly allocated to:
Group 1: diclofenac 75 mg i.m. (16 participants)
Group 2: butyl-scopolamine bromide 20 mg i.m. (15 participants)
15 participants who were allocated to 1 mg glucagon treatment were not included in the
analysis
In all of the groups, a rescue therapy was planned after 60 minutes with the same drugs
The intensity of pain was estimated before and 30 minutes after injection with an
analogue chromatic continue scale (0 to 100 mm)
Outcomes Lack of pain relief was observed in 5 out of 16 participants on diclofenac and in 10 out
of 15 on scopolamine
No side effects were experienced in participants on diclofenac or scopolamine; con-
versely, in 3 participants on glucagon a sharp increase in glycaemia was observed without
concomitant changes in serum amylase. All 3 treatments caused a significant decrease in
systolic blood pressure
No gallstone-related complications were reported.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear
Allocation concealment (selection bias) Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Unclear risk There is insufficient information to assess
whether themagnitude and direction of the
observed effect is related to selective out-
come reporting
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Injection was made by a member of the
medical staff not involved in the subse-
quent follow-up. The participant was un-
aware of the identity of the treatment ad-
ministered
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Grossi 1986 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Injection was made by a member of the
medical staff not involved in the subse-
quent follow-up
Other bias Low risk No risk of for-profit bias on the side of re-
searchers, manufacturers, or funding bod-
ies or any personal conflicts by the authors
of the trial publication were observed
Henderson 2002
Methods Randomised clinical trial with parallel-group design.
Participants 534 consecutive participants attending the emergency department with a history and
physical examination consistent with biliary colic were enrolled
Inclusion criteria: age between 18 and 65 years, pain of moderate to severe intensity on a
4-point (none, mild, moderate, severe) verbal rating system, abdominal pain felt by the
clinician to originate from the gallbladder (e.g. right upper quadrant or epigastric pain)
, and a history of known cholelithiasis or a bedside, emergency physician-performed
ultrasonography consistent with cholelithiasis
Exclusion criteria: age under 18 years or over 65 years, history of known cholecystectomy,
pregnancy, history of renal insufficiency, history of active peptic ulcer disease in the
previous 6 months, history of bleeding, anticoagulation regimen in the previous 4 weeks,
immunocompromised because of different underlying medical conditions (including
diabetes mellitus, HIV, end-stage hepatic disease, and cancer), and a patient history of
allergy to any opioid or non-opioid analgesic
Interventions Of 534 enrolled participants, 324 completed the protocol and had completed study
forms
Group 1: ketorolac 30 mg i.v. (175 participants)
Group 2: pethidine 50 mg i.v. (149 participants)
Immediately before drug administration, participants were asked by the physician to
rate the severity of their pain using a 4-point visual rating system (VRS) (none, mild,
moderate, or severe) and aVAS.TheVASwas a 100-millimetre horizontal, not-numbered
scale bounded by the descriptors “no pain” and “maximum pain”. At time 0 (baseline),
the study medication was administered and vital signs were recorded. At 30 minutes, 1
h, and 2 h, vital signs were repeated, and the participants pain was reassessed using both
the VRS and VAS
Participants with inadequate subjective pain relief at 1 h were given a supplementary
dose of pethidine 50 mg i.v. as a rescue drug. Also, at 2 h participants were asked to rate
overall pain relief on a 5-point categorical scale (none, a little, some, a lot, complete)
, and both participants and physicians were asked to rate drug tolerability (poor, fair,
good, very good, or excellent)
Outcomes No significant difference in pain relief was found between the 2 groups in the VRS at
30 minutes, 1 h, or 2 h. No significant differences were found between the 2 groups in
the change in the mean VAS at 30 minutes or at 1 h. At 2 hours, ketorolac was equal in
efficacy to pethidine for analgesia with a total change in the VAS score of 6.7 cm vs 6.
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Henderson 2002 (Continued)
2 cm (P = 0.29). Lack of pain relief (i.e. the need for a further dose of pethidine) at 1
hour of observation was observed in 129 out of 175 participants treated with ketorolac
versus 125 out of 149 treated with pethidine (P =NS).Drowsiness was themost frequent
side effect, observed in 34.6% of participants treated with ketorolac and 42.1% of those
treated with pethidine (P = NS). Nausea and dizziness were significantly more frequent
in the pethidine group than in the ketorolac group (16.4% vs 6.8% and 17.9% vs 6.
8%)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computed-generated list of random num-
ber.
Allocation concealment (selection bias) Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk The trial protocol is available, and all of
the trial’s prespecified outcomes that are of
interest in the review have been reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study drugs were administered by the par-
ticipant primary nurse and were identical
in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome assessment was performed by
the same physician/personnel who admin-
istered treatment
Other bias Low risk No risk of for-profit bias on the side of re-
searchers, manufacturers, or funding bod-
ies or any personal conflicts by the authors
of the trial publication were observed
Kumar 2004
Methods Randomised clinical trial with parallel-group design
Participants The trial included 72 consecutive participants with biliary colic, presenting with severe
pain, lasting less than 6 h, attending the emergency department. The presence of gall-
stones was confirmed by ultrasonography
Exclusion criteria were: severe pain lasting more than 6 h, fever, leucocytosis, abnormal
liver function tests, signs of peritonitis or ultrasound evidence of acute cholecystitis, or
42Non-steroid anti-inflammatory drugs for biliary colic (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kumar 2004 (Continued)
common bile duct stones. The trial also excluded people who had received analgesics or
antibiotics before hospital presentation, and those with pregnancy or significant systemic
disease such as diabetes mellitus, uraemia, cardiovascular or respiratory disease. Similarly,
people with contraindications to receive diclofenac (acute peptic ulcer, gastrointestinal
bleeding, asthma or NSAID-induced allergy) or hyoscine (glaucoma, prostatic hypertro-
phy with urinary retention, gastrointestinal mechanical stenosis, porphyria), and those
receiving medications likely to have adverse interactions with diclofenac or hyoscine
(lithium, digoxin, L-Dopa, antidepressants, phenothiazines) were also excluded from the
trial
Interventions Group 1: diclofenac single dose of 75 mg i.m. (36 participants)
Group 2: hyoscine-N-butylbromide single dose of 20 mg i.m. (36 participants)
In both groups, pain severity was recorded on a 10-point VAS 30 min, 1 h, 2 h, and 4
h after treatment. Participants were then closely followed up to 72 h for the persistence
or relapse of pain, or the development of acute cholecystitis (which was confirmed by
ultrasonography). No rescue therapy was planned
Outcomes No participant in either group had complete pain relief within 1 hour from having
received injection. However, the number of participants without complete pain relief at
2 h was significantly less frequent in the group receiving diclofenac as compared to the
group receiving scopolamine (16 out of 36 versus 29 out of 36). Pain intensity by VAS
decreased from 9.58 ± 0.54 to 5.15 ± 1.2 in the diclofenac group and from 9.61 ± 0.48
to 5.76 ± 0.97 in the hyoscine group
Progression to cholecystitis was observed in 6 out of 36 participants in the diclofenac
group and in 19 out of 36 participants in the hyoscine group (P = 0.003)
The trial did not report data on adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized block design
Allocation concealment (selection bias) Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk The trial protocol is available, and all of the
trial’s prespecified outcomes of interest to
the review have been reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No information given.
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information given.
Other bias Low risk No risk of for-profit bias on the side of re-
searchers, manufacturers, or funding bod-
ies or any personal conflicts by the authors
of the trial publication were observed
Lundstam 1985
Methods Randomised clinical trial with parallel-group design
Participants 47 participants presenting at the emergency room for biliary colic pain. Only people with
a confirmed diagnosis of cholelithiasis (oral cholecystogram or ultrasound or operation)
were included in the trial
Interventions Group 1 (25 participants): diclofenac sodium (50 mg i.m.)
Group 2 (22 participants): placebo (saline) (50 mg i.m.)
Before injection the surgeon rated the pain intensity as either moderate or severe. The
analgesic effect was evaluated at 15 and 30 minutes as nil, partial, or complete relief. The
participant also rated the pain on a 100-millimetre VAS before and 30 minutes after the
injection
Outcomes Overall, at 30 minutes after injection lack of complete pain relief was observed in 14 out
of 25 participants in the diclofenac group versus 16 out of 20 participants in the placebo
group. Pain estimated on the visual scale was reduced by 58% (from 63 ± 5 to 27 ± 5
mm) in the diclofenac group and by 39% (from 66 ± 4 to 41 ± 6 mm) in the placebo
group. As from clinical evaluation, cholecystitis developed in 8 out of 25 participants on
diclofenac versus 7 out of 22 participants on saline
No participant had evidence of common bile duct disease or pancreatitis
No serious side effects were recorded in the 2 groups, even if a slight but significant
decrease in systolic blood pressure was reported in both groups after the treatment
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear
Allocation concealment (selection bias) Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
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Lundstam 1985 (Continued)
Selective reporting (reporting bias) Unclear risk There is insufficient information to assess
whether themagnitude and direction of the
observed effect is related to selective out-
come reporting
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No information given.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No information given.
Other bias Low risk No risk of for-profit bias on the side of re-
searchers, manufacturers, or funding bod-
ies or any personal conflicts by the authors
of the trial publication were observed
Magrini 1985
Methods Randomised clinical trial
Participants 60 participants presenting at 2 Italian emergency wards with biliary colic were enrolled
Exclusion criteria were: a history of haemorrhagic disorder; peptic ulcer; severe hepatic,
renal respiratory, or cardiac insufficiency; and diabetes mellitus. Severely disabled people,
people unable to co-operate, narcotic addicts, people with known hypersensitivity to
ketoprofen or acetylsalicylic-acid were also excluded
Pain intensity was assessed before and 15, 30, 60, 120, and 180 minutes after treatment
by asking the participants to rate pain according to a 5-point scale (0 = none, 1 = mild,
2 = moderate, 3 = severe, 4 = very severe)
Rescue analgesic therapy was planned after 3 hours from the beginning of the trial with
the same drug
Interventions Group 1: ketoprofen 200 mg i.v. (20 participants)
Group 2: lysine acetylsalicylate, 1.8 g i.v. (20 participants)
Group 3: placebo 10 mL i.v. (20 participants)
Only group 1 and group 3 were considered in this review.
Outcomes 30 minutes after injection, lack of complete pain relief was observed in 3 out of 20
participants in ketoprofen group, 4 out of 20 participants in the lysine acetylsalicylic-
acid group, and 16 out of 20 participants in the placebo group
All treatments were well tolerated.
Only 1 participant experienced vomiting (in the acetylsalicylic-acid group) and 1 drowsi-
ness (in the ketoprofen group). No complication was reported
Adverse eventswere: restlessness (2with placebo and1with acetylsalicylic-acid), vomiting
(1 participant with acetylsalicylic-acid), and drowsiness (1 case with ketoprofen). Blood
pressure was slightly but significantly decreased in the 2 treatment groups but not in the
placebo subset
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Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear
Allocation concealment (selection bias) Unclear risk Unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Unclear risk There is insufficient information to assess whether the mag-
nitude and direction of the observed effect is related to se-
lective outcome reporting
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The 3 drugs were given from identical vials of identical ap-
pearance, containing a freeze-dried powder to be dissolved
in 10 mL sterile water and injected in a 2-minutes intra-
venous dose
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The outcome assessment was performed by the same physi-
cian/personnel who administered treatment
Other bias Low risk No risk of for-profit bias on the side of researchers, manu-
facturers, or funding bodies or any personal conflicts by the
authors of the trial publication were observed
Olsen 2008
Methods Randomised clinical trial
Participants 51 participants presenting with suspected biliary colic, 5 of them refused and thus 46
were enrolled and randomised
Interventions - ketorolac 30 mg i.v. (21 participants)
- butorphanol 1 mg i.v. (25 participants)
Outcomes Pain level was assessed using 1-to-10 “faces” visual analogue pain scale basal and at 15
and 30 minutes after medication infusion
Notes
Risk of bias
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Olsen 2008 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The pharmacy supplied the participants with their medica-
tion via a computed-generated randomisation sequence
Allocation concealment (selection bias) Low risk Medicaments were given by a nurse uninvolved in the study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Unclear risk There is insufficient information to assess whether the mag-
nitude and direction of the observed effect is related to se-
lective outcome reporting
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The treating physician and the participants were blind to the
study medication used. At the end of the study, when all the
participants were enrolled and data collected, the pharmacy
provided information as to which study drug was actually
administered to each participant
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Drug administration was made by a nurse not involved in
the subsequent follow-up
Other bias Low risk No risk of for-profit bias on the side of researchers, manu-
facturers, or funding bodies or any personal conflicts by the
authors of the trial publication were observed
ED: emergency department; i.m.: intramuscularly; i.v.: intravenously; NS: non-significant; NSAIDs: non-steroid anti-inflammatory
drugs; VAS: visual analogue scale.
Hyoscine butylbromide, butyl-scopolamine bromide, and scopolamine is the one and the same drug.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Chang 2002 Not relevant as it refers to dental pain.
Chaudhary 1999 The study compares 2 NSAIDs.
Kantor 1986 It is a review.
Marsala 1986 The study compares a different type of administration of naproxen sodium (i.v. versus i.m.)
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Niinikoski 1984 The study compares 2 NSAIDs.
Thornell 1979 It is not a randomised clinical trial.
i.m.: intramuscularly; i.v.: intravenously; NSAIDs: non-steroid anti-inflammatory drugs
Characteristics of ongoing studies [ordered by study ID]
NCT02268955
Trial name or title Assessment of the analgesic efficacy of intravenous ibuprofen in biliary colic
Methods Randomised clinical trial
Participants Patients referring at the emergency department for biliary colic
Interventions Drug: ibuprofen i.v.; placebo: saline
Outcomes Primary: pain level: VAS at 15 minutes post-administration
Secondary: changes in pain level (VAS) at 30, 45, 60, and 90 minutes post-administration
Starting date 16 September 2014
Contact information Dr Dan Quan by phone
Dr Mary Mulrow by phone
Notes Eligibility 18.55 years
i.v.: intravenously; VAS: visual analogue scale.
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D A T A A N D A N A L Y S E S
Comparison 1. NSAIDs versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Lack of pain relief 5 208 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.19, 0.40]
2 Cholelithiasis-related
complications
3 140 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.38, 1.15]
Comparison 2. NSAIDs versus opioids
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Lack of pain relief 4 459 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.47, 2.07]
2 Cholelithiasis-related
complications
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 3. NSAIDs versus spasmolytic drugs
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Lack of pain relief 4 190 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.37, 0.71]
2 Cholelithiasis-related
complications
2 104 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.12, 0.57]
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Analysis 1.1. Comparison 1 NSAIDs versus placebo, Outcome 1 Lack of pain relief.
Review: Non-steroid anti-inflammatory drugs for biliary colic
Comparison: 1 NSAIDs versus placebo
Outcome: 1 Lack of pain relief
Study or subgroup NSAIDs Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Akriviadis 1997 5/27 19/26 23.9 % 0.25 [ 0.11, 0.58 ]
Broggini 1984 5/14 16/16 19.1 % 0.38 [ 0.19, 0.74 ]
Goldman 2001 3/20 19/20 23.5 % 0.16 [ 0.06, 0.45 ]
Lundstam 1985 5/25 10/20 13.7 % 0.40 [ 0.16, 0.98 ]
Magrini 1985 4/20 16/20 19.8 % 0.25 [ 0.10, 0.62 ]
Total (95% CI) 106 102 100.0 % 0.27 [ 0.19, 0.40 ]
Total events: 22 (NSAIDs), 80 (Placebo)
Heterogeneity: Chi2 = 2.70, df = 4 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 6.67 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours NSAIDs Favours placebo
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Analysis 1.2. Comparison 1 NSAIDs versus placebo, Outcome 2 Cholelithiasis-related complications.
Review: Non-steroid anti-inflammatory drugs for biliary colic
Comparison: 1 NSAIDs versus placebo
Outcome: 2 Cholelithiasis-related complications
Study or subgroup NSAIDs Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Akriviadis 1997 13/27 21/26 65.1 % 0.60 [ 0.39, 0.92 ]
Goldman 2001 0/20 4/20 3.6 % 0.11 [ 0.01, 1.94 ]
Lundstam 1985 8/25 7/22 31.3 % 1.01 [ 0.44, 2.32 ]
Total (95% CI) 72 68 100.0 % 0.66 [ 0.38, 1.15 ]
Total events: 21 (NSAIDs), 32 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 2.70, df = 2 (P = 0.26); I2 =26%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours NSAIDs Favours placebo
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Analysis 2.1. Comparison 2 NSAIDs versus opioids, Outcome 1 Lack of pain relief.
Review: Non-steroid anti-inflammatory drugs for biliary colic
Comparison: 2 NSAIDs versus opioids
Outcome: 1 Lack of pain relief
Study or subgroup NSAIDs Opioids Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Camp 1992 2/30 6/29 16.2 % 0.32 [ 0.07, 1.47 ]
Dula 2001 2/16 4/14 15.9 % 0.44 [ 0.09, 2.04 ]
Henderson 2002 46/175 24/149 42.5 % 1.63 [ 1.05, 2.54 ]
Olsen 2008 6/21 5/25 25.4 % 1.43 [ 0.51, 4.02 ]
Total (95% CI) 242 217 100.0 % 0.98 [ 0.47, 2.07 ]
Total events: 56 (NSAIDs), 39 (Opioids)
Heterogeneity: Tau2 = 0.29; Chi2 = 6.23, df = 3 (P = 0.10); I2 =52%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours NSAIDs Favours opioids
Analysis 2.2. Comparison 2 NSAIDs versus opioids, Outcome 2 Cholelithiasis-related complications.
Review: Non-steroid anti-inflammatory drugs for biliary colic
Comparison: 2 NSAIDs versus opioids
Outcome: 2 Cholelithiasis-related complications
Study or subgroup NSAIDs Opioids Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dula 2001 2/16 2/14 0.88 [ 0.14, 5.42 ]
0.1 0.2 0.5 1 2 5 10
Favours NSAIDs Favours opioids
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Analysis 3.1. Comparison 3 NSAIDs versus spasmolytic drugs, Outcome 1 Lack of pain relief.
Review: Non-steroid anti-inflammatory drugs for biliary colic
Comparison: 3 NSAIDs versus spasmolytic drugs
Outcome: 1 Lack of pain relief
Study or subgroup NSAIDs Spasmolytic drugs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al Waili 1998 6/16 9/16 16.1 % 0.67 [ 0.31, 1.43 ]
Camp 1992 2/30 7/25 13.6 % 0.24 [ 0.05, 1.05 ]
Grossi 1986 5/16 10/15 18.4 % 0.47 [ 0.21, 1.05 ]
Kumar 2004 16/36 29/36 51.8 % 0.55 [ 0.37, 0.82 ]
Total (95% CI) 98 92 100.0 % 0.51 [ 0.37, 0.71 ]
Total events: 29 (NSAIDs), 55 (Spasmolytic drugs)
Heterogeneity: Chi2 = 1.67, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 4.04 (P = 0.000053)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NDSAIDs Favours spasmolytic drugs
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Analysis 3.2. Comparison 3 NSAIDs versus spasmolytic drugs, Outcome 2 Cholelithiasis-related
complications.
Review: Non-steroid anti-inflammatory drugs for biliary colic
Comparison: 3 NSAIDs versus spasmolytic drugs
Outcome: 2 Cholelithiasis-related complications
Study or subgroup NSAIDs Spasmolytic drugs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Al Waili 1998 0/16 5/16 22.4 % 0.09 [ 0.01, 1.52 ]
Kumar 2004 6/36 19/36 77.6 % 0.32 [ 0.14, 0.70 ]
Total (95% CI) 52 52 100.0 % 0.27 [ 0.12, 0.57 ]
Total events: 6 (NSAIDs), 24 (Spasmolytic drugs)
Heterogeneity: Chi2 = 0.74, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 3.39 (P = 0.00069)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours NSAIDs Favours spasmolytic drugs
A P P E N D I C E S
Appendix 1. Search strategies
Database Date of search Search terms
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
31 July 2016 Anti-inflammatory or NSAID and (biliary colic or gall bladder
or cholelithiasis)
Cochrane Central Register of Controlled
Trials (CENTRAL) (Cochrane Library)
2016, Issue 5 #1MeSH descriptor Anti-Inflammatory Agents, Non-Steroidal
explode all trees
#2 (anti-inflammatory agent) and (non-steroid*)
#3 NSAID*
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Biliary Tract Diseases explode all trees
#6 MeSH descriptor Colic explode all trees
#7 (#5 AND #6)
#8 (biliary colic*)
#9 (#7 OR #8)
#10 (#4 AND #9)
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(Continued)
MEDLINE (Ovid SP) 1946 to 31 July 2016 #1 explode “Anti-Inflammatory-Agents-Non-Steroidal”/ all
subheadings
#2 non-steroid* anti-inflammatory or antinflammatory drug*
or antinflammatory agent* or NSAIDs or non steroid* antin-
flammatory
#3 #1 or #2
#4 biliary colic* or biliary disease* or biliary pain*
#5 biliary complication* or biliary colic* complication* or acute
cholecystitis or cholelithiasis-related complication* or acute
pancreatitis or cholangitis or jaundice
#6 #4 or #5
#7 #3 and #6
#8 random* or placebo* or blind* or meta-analys* or Random-
ized controlled trial* or randomised clinical trial or controlled
trial* or quasi randomized trial*
#9 #7 and #8
Embase (Ovid SP) 1974 to 31 July 2016 #1 explode “antiinflammatory-agent”/ all subheadings
#2 antinflammatory drug* or antinflammatory agent* or
NSAIDs or non steroid* antinflammatory
#3 #1 or #2
#4 biliary colic* or biliary disease* or biliary pain or biliary com-
plication* or biliary colic* complication* or acute cholecystitis
or cholelithiasis-related complication* or acute pancreatitis or
cholangitis or jaundice
#5 explode “colic”/ all subheadings
#6 explode “biliary-tract-disease”/ all subheadings
#7 #4 or #5 or #6
#8 #3 and #7
#9 random* or placebo* or meta-analys* or blind* or Random-
ized controlled trial* or randomised clinical trial or controlled
trial* or quasi randomized trial*
#10 #8 and #9
#11 animal*
#12 #10 not #11
Science Citation Index Expanded (Web of
Science)
1900 to 31 July 2016 #5 #3 and #4
#4 TS=biliary colic*
#3 6#1 or #2
#2 TS=NSAID*
#1 TS=(Anti-Inflammatory Agent* and Non-Steroid*)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The main outcome as stated in the protocol was initially pain relief (Colli 2007). One of the peer reviewers suggested changing the
outcome into the proportion of participants who had ’lack of pain relief ’, and we agreed to this. We thus divided outcomes into
primary (1. mortality and 2. lack of pain relief ) and secondary (1. number of people with cholelithiasis-related complications (e.g. acute
cholecystitis, acute pancreatitis, jaundice, cholangitis; number of people manifesting bleeding from operative intervention or ERCP
less than 9, or both; 2. quality of life; 3. drug-related complications and adverse events, expressed as the number of people experiencing
any event (e.g. gastrointestinal bleeding, cutaneous rash, renal function impairment, cardiovascular events, and any other described in
the trials); 4. quantification of pain relief in which intensity of pain was rated in the trials on a quantitative scale in the following way:
the difference of pain intensity after 30 or 60 minutes from treatment compared with pain intensity at enrolment. Differences in the
scale used for rating pain were accounted for by multiplying by 10 for the 10-point scale, by 20 for the five-point scale, and by 25 for
the four-point scale. We left unchanged scales in which pain was rated on a 100-millimetre analogue chromatic rating system (data
synthesis or extraction); 5. the time needed to obtain pain relief: complete pain relief or any small amount of pain relief (as defined by
the different trials).
We have added information about Trial Sequential Analysis at the review stage, as at the time of the protocol preparation it was not
completely developed.
We have added the incomplete outcome data ’Risk of bias’ domain to the ’Risk of bias’ assessment.
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